SAB Biotherapeutics (SABS) to Release Earnings on Friday

SAB Biotherapeutics (NASDAQ:SABS) is projected to post its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect SAB Biotherapeutics to post earnings of ($0.16) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 9, 2026 at 7:00 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). On average, analysts expect SAB Biotherapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SAB Biotherapeutics Stock Up 2.2%

NASDAQ:SABS opened at $3.78 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46. The company’s fifty day moving average price is $4.03 and its 200-day moving average price is $3.41. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $6.60. The firm has a market capitalization of $192.59 million, a P/E ratio of -1.63 and a beta of 0.59.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. HC Wainwright lowered their price target on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Guggenheim assumed coverage on SAB Biotherapeutics in a report on Friday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. Chardan Capital upped their target price on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Zacks Research lowered SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. Finally, Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds have recently bought and sold shares of SABS. Vivo Capital LLC purchased a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $22,954,000. RA Capital Management L.P. acquired a new position in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $8,847,000. Woodline Partners LP purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at approximately $5,730,000. Perceptive Advisors LLC acquired a new stake in SAB Biotherapeutics in the 4th quarter valued at $3,004,000. Finally, Balyasny Asset Management L.P. acquired a new stake in SAB Biotherapeutics in the 4th quarter valued at $1,778,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.